Company intelligence / Profile preview

Xizhou Pharmaceutical Technology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Xizhou Pharmaceutical Technology is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative small molecule therapeutics for metabolic diseases. The company's primary focus is on next-generation treatments for type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Their lead candidate, XZP-5610, is an orally bioavailable small molecule GLP-1 receptor agonist designed to provide a more convenient alternative to injectable therapies. Xizhou Pharmaceutical Technology leverages its expertise in medicinal chemistry to optimize the pharmacological profiles of incretin-based therapies.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Xizhou Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xizhou Pharmaceutical Technology.

Explore the full profile